-
1
-
-
77950475252
-
Prolactinomas
-
Klibanski A. Prolactinomas. N Engl J Med 2010, 362:1219-1226.
-
(2010)
N Engl J Med
, vol.362
, pp. 1219-1226
-
-
Klibanski, A.1
-
2
-
-
0023813607
-
Effects of prolactin and estrogen deficiency in amenorrheic bone loss
-
Klibanski A., Biller B.M., Rosenthal D.I., et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988, 67:124-130.
-
(1988)
J Clin Endocrinol Metab
, vol.67
, pp. 124-130
-
-
Klibanski, A.1
Biller, B.M.2
Rosenthal, D.I.3
-
3
-
-
0026783954
-
A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia
-
Schlechte J., Walker L., Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992, 75:698-703.
-
(1992)
J Clin Endocrinol Metab
, vol.75
, pp. 698-703
-
-
Schlechte, J.1
Walker, L.2
Kathol, M.3
-
4
-
-
0019382626
-
Hyperprolactinemia-a significant factor in female infertility
-
Kredentser J.V., Hoskins C.F., Scott J.Z. Hyperprolactinemia-a significant factor in female infertility. Am J Obstet Gynecol 1981, 139:264-267.
-
(1981)
Am J Obstet Gynecol
, vol.139
, pp. 264-267
-
-
Kredentser, J.V.1
Hoskins, C.F.2
Scott, J.Z.3
-
5
-
-
0021991283
-
Menstrual pattern and ovarian function in women with hyperprolactinemia
-
Bahamondes L., Faundes A., Tambascia M., et al. Menstrual pattern and ovarian function in women with hyperprolactinemia. Int J Gynaecol Obstet 1985, 23:31-36.
-
(1985)
Int J Gynaecol Obstet
, vol.23
, pp. 31-36
-
-
Bahamondes, L.1
Faundes, A.2
Tambascia, M.3
-
6
-
-
0023201288
-
Suppression of pulsatile LH secretion, pituitary GnRH receptor content and pituitary responsiveness to GnRH by hyperprolactinemia in the male rat
-
Fox S.R., Hoefer M.T., Bartke A., et al. Suppression of pulsatile LH secretion, pituitary GnRH receptor content and pituitary responsiveness to GnRH by hyperprolactinemia in the male rat. Neuroendocrinology 1987, 46:350-359.
-
(1987)
Neuroendocrinology
, vol.46
, pp. 350-359
-
-
Fox, S.R.1
Hoefer, M.T.2
Bartke, A.3
-
7
-
-
0021870960
-
Hyperprolactinemia inhibits gonadotropin-releasing hormone (GnRH) stimulation of the number of pituitary GnRH receptors
-
Garcia A., Herbon L., Barkan A., et al. Hyperprolactinemia inhibits gonadotropin-releasing hormone (GnRH) stimulation of the number of pituitary GnRH receptors. Endocrinology 1985, 117:954-959.
-
(1985)
Endocrinology
, vol.117
, pp. 954-959
-
-
Garcia, A.1
Herbon, L.2
Barkan, A.3
-
8
-
-
0034101143
-
Abnormal LH pulsatility in women with hyperprolactinemic amenorrhea normalizes after bromocriptine treatment: deconvolution-based assessment
-
Sartorio A., Pizzocaro A., Liberati D., et al. Abnormal LH pulsatility in women with hyperprolactinemic amenorrhea normalizes after bromocriptine treatment: deconvolution-based assessment. Clin Endocrinol (Oxf) 2000, 52:703-712.
-
(2000)
Clin Endocrinol (Oxf)
, vol.52
, pp. 703-712
-
-
Sartorio, A.1
Pizzocaro, A.2
Liberati, D.3
-
9
-
-
0021159754
-
Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: response to bromocriptine
-
Sauder S.E., Frager M., Case G.D., et al. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: response to bromocriptine. J Clin Endocrinol Metab 1984, 59:941-948.
-
(1984)
J Clin Endocrinol Metab
, vol.59
, pp. 941-948
-
-
Sauder, S.E.1
Frager, M.2
Case, G.D.3
-
10
-
-
0017647392
-
Hypogonadism, galactorrhea and hyperprolactinemia: evaluation of pituitary gonadotrophins reserve before and under bromocriptine
-
Asfour M., L'Hermite M., Hedouin-Quincampoix M., et al. Hypogonadism, galactorrhea and hyperprolactinemia: evaluation of pituitary gonadotrophins reserve before and under bromocriptine. Acta Endocrinol (Copenh) 1977, 84:738-749.
-
(1977)
Acta Endocrinol (Copenh)
, vol.84
, pp. 738-749
-
-
Asfour, M.1
L'Hermite, M.2
Hedouin-Quincampoix, M.3
-
11
-
-
0015897591
-
Luteinizing hormone and follicle stimulating hormone-releasing hormone test in patients with hypothalamic-pituitary-gonadal dysfunction
-
Mortimer C.H., Besser G.M., McNeilly A.S., et al. Luteinizing hormone and follicle stimulating hormone-releasing hormone test in patients with hypothalamic-pituitary-gonadal dysfunction. Br Med J 1973, 4:73-77.
-
(1973)
Br Med J
, vol.4
, pp. 73-77
-
-
Mortimer, C.H.1
Besser, G.M.2
McNeilly, A.S.3
-
12
-
-
0016550926
-
Specific receptors for prolactin in the ovary
-
Saito T., Saxena B.B. Specific receptors for prolactin in the ovary. Acta Endocrinol (Copenh) 1975, 80:126-137.
-
(1975)
Acta Endocrinol (Copenh)
, vol.80
, pp. 126-137
-
-
Saito, T.1
Saxena, B.B.2
-
13
-
-
0016714087
-
Demonstration of a specific receptor for prolactin in porcine granulosa cells
-
Rolland R., Hammond J.M. Demonstration of a specific receptor for prolactin in porcine granulosa cells. Endocr Res Commun 1975, 2:281-298.
-
(1975)
Endocr Res Commun
, vol.2
, pp. 281-298
-
-
Rolland, R.1
Hammond, J.M.2
-
14
-
-
0019830067
-
Prolactin inhibits oestrogen synthesis in the ovary
-
Dorrington J., Gore-Langton R.E. Prolactin inhibits oestrogen synthesis in the ovary. Nature 1981, 290:600-602.
-
(1981)
Nature
, vol.290
, pp. 600-602
-
-
Dorrington, J.1
Gore-Langton, R.E.2
-
15
-
-
0020438109
-
Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17β estradiol in the human ovary
-
Demura R., Ono M., Demura H., et al. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17β estradiol in the human ovary. J Clin Endocrinol Metab 1982, 54:1246-1250.
-
(1982)
J Clin Endocrinol Metab
, vol.54
, pp. 1246-1250
-
-
Demura, R.1
Ono, M.2
Demura, H.3
-
18
-
-
0029095150
-
Polycystic ovary syndrome
-
Franks S. Polycystic ovary syndrome. N Engl J Med 1995, 333:853-861.
-
(1995)
N Engl J Med
, vol.333
, pp. 853-861
-
-
Franks, S.1
-
19
-
-
0035201094
-
The surgical management of pituitary adenomas in a series of 3,093 patients
-
Jane J.A., Laws E.R. The surgical management of pituitary adenomas in a series of 3,093 patients. J Am Coll Surg 2001, 193:651-659.
-
(2001)
J Am Coll Surg
, vol.193
, pp. 651-659
-
-
Jane, J.A.1
Laws, E.R.2
-
21
-
-
0022501528
-
Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumors
-
Schlechte J.A., Sherman B.M., Chapler F.K., et al. Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab 1986, 62:1296-1301.
-
(1986)
J Clin Endocrinol Metab
, vol.62
, pp. 1296-1301
-
-
Schlechte, J.A.1
Sherman, B.M.2
Chapler, F.K.3
-
22
-
-
0036358612
-
Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lesions from long-term follow-up
-
Thompson J.A., Gray C.E., Teasdale G.M. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lesions from long-term follow-up. Neurosurgery 2002, 50:36-40.
-
(2002)
Neurosurgery
, vol.50
, pp. 36-40
-
-
Thompson, J.A.1
Gray, C.E.2
Teasdale, G.M.3
-
23
-
-
0015608836
-
Suppression of pituitary tumor growth and function by ergot alkaloids
-
MacLeod R.M., Lehmeyer J.E. Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res 1973, 33:849-855.
-
(1973)
Cancer Res
, vol.33
, pp. 849-855
-
-
MacLeod, R.M.1
Lehmeyer, J.E.2
-
24
-
-
0036933895
-
Medical management of pituitary adenomas: structural and ultrastructural changes
-
Asa S.L., Ezzat S. Medical management of pituitary adenomas: structural and ultrastructural changes. Pituitary 2002, 5:133-139.
-
(2002)
Pituitary
, vol.5
, pp. 133-139
-
-
Asa, S.L.1
Ezzat, S.2
-
25
-
-
0021994564
-
Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study
-
Molitch M.E., Elton R.L., Blackwell R.E., et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985, 60:698-705.
-
(1985)
J Clin Endocrinol Metab
, vol.60
, pp. 698-705
-
-
Molitch, M.E.1
Elton, R.L.2
Blackwell, R.E.3
-
26
-
-
0026742206
-
Dopamine agonists and pituitary tumor shrinkage
-
Bevan J.S., Webster J., Burke C.W., et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992, 13:220-240.
-
(1992)
Endocr Rev
, vol.13
, pp. 220-240
-
-
Bevan, J.S.1
Webster, J.2
Burke, C.W.3
-
27
-
-
0028146981
-
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
-
Webster J., Piscitelli G., Polli A., et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994, 331:904-909.
-
(1994)
N Engl J Med
, vol.331
, pp. 904-909
-
-
Webster, J.1
Piscitelli, G.2
Polli, A.3
-
28
-
-
0031017930
-
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment
-
Colao A., Di Sarno A., Sarnacchiaro S., et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997, 82:876-883.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 876-883
-
-
Colao, A.1
Di Sarno, A.2
Sarnacchiaro, S.3
-
29
-
-
0029653901
-
Cabergoline versus bromocriptine for hyperprolactinaemic amenorrhea. Results of a multicentric, randomized, double-blind trial in France
-
Pascal-Vigneron V., Weryha G., Bosc M., et al. Cabergoline versus bromocriptine for hyperprolactinaemic amenorrhea. Results of a multicentric, randomized, double-blind trial in France. Presse Med 1995, 24:753-757.
-
(1995)
Presse Med
, vol.24
, pp. 753-757
-
-
Pascal-Vigneron, V.1
Weryha, G.2
Bosc, M.3
-
30
-
-
0022521699
-
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine
-
Demont J.F., Rostin M., Dueymes J.M., et al. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol 1986, 9:200-201.
-
(1986)
Clin Neuropharmacol
, vol.9
, pp. 200-201
-
-
Demont, J.F.1
Rostin, M.2
Dueymes, J.M.3
-
31
-
-
0023736795
-
Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease
-
McElvaney N.G., Wilcox P.G., Churg A., et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988, 148:2231-2236.
-
(1988)
Arch Intern Med
, vol.148
, pp. 2231-2236
-
-
McElvaney, N.G.1
Wilcox, P.G.2
Churg, A.3
-
32
-
-
33845974147
-
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
-
Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356:39-46.
-
(2007)
N Engl J Med
, vol.356
, pp. 39-46
-
-
Zanettini, R.1
Antonini, A.2
Gatto, G.3
-
33
-
-
33845986031
-
Dopamine agonists and the risk of cardiac-valve regurgitation
-
Schade R., Andersohn F., Suissa S., et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007, 356:29-38.
-
(2007)
N Engl J Med
, vol.356
, pp. 29-38
-
-
Schade, R.1
Andersohn, F.2
Suissa, S.3
-
34
-
-
63049114030
-
Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies
-
Bogazzi F., Manetti L., Raffaelli V., et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008, 31:1119-1123.
-
(2008)
J Endocrinol Invest
, vol.31
, pp. 1119-1123
-
-
Bogazzi, F.1
Manetti, L.2
Raffaelli, V.3
-
35
-
-
77749234191
-
Potential cardiac valve effects of dopamine agonists in hyperprolactinemia
-
Valassi E., Klibanski A., Biller B.M. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010, 95:1025-1033.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 1025-1033
-
-
Valassi, E.1
Klibanski, A.2
Biller, B.M.3
-
36
-
-
33644595738
-
Quinagolide-a valuable treatment option for hyperprolactinaemia
-
Barlier A., Jaquet P. Quinagolide-a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 2006, 154:187-195.
-
(2006)
Eur J Endocrinol
, vol.154
, pp. 187-195
-
-
Barlier, A.1
Jaquet, P.2
-
37
-
-
0029873353
-
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation
-
Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996, 14:228-238.
-
(1996)
Drug Saf
, vol.14
, pp. 228-238
-
-
Webster, J.1
-
38
-
-
0023185499
-
Bromocriptine in pregnancy: safety aspects
-
Krupp P., Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987, 65:823-827.
-
(1987)
Klin Wochenschr
, vol.65
, pp. 823-827
-
-
Krupp, P.1
Monka, C.2
-
39
-
-
33644870007
-
Prolactinomas and pregnancy
-
Bronstein M.D. Prolactinomas and pregnancy. Pituitary 2005, 8:31-38.
-
(2005)
Pituitary
, vol.8
, pp. 31-38
-
-
Bronstein, M.D.1
-
40
-
-
78049319324
-
Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature
-
Stalldecker G., Mallea-Gil M.S., Guitelman M., et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010, 13(4):345-350.
-
(2010)
Pituitary
, vol.13
, Issue.4
, pp. 345-350
-
-
Stalldecker, G.1
Mallea-Gil, M.S.2
Guitelman, M.3
-
41
-
-
77954508608
-
Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas
-
Ono M., Miki N., Amano K., et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 2010, 95:2672-2679.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 2672-2679
-
-
Ono, M.1
Miki, N.2
Amano, K.3
-
42
-
-
77954873663
-
Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinemic women
-
Lebbe M., Hubinont C., Bernard P., et al. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinemic women. Clin Endocrinol 2010, 73:236-242.
-
(2010)
Clin Endocrinol
, vol.73
, pp. 236-242
-
-
Lebbe, M.1
Hubinont, C.2
Bernard, P.3
-
43
-
-
0242351840
-
Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity and the effects of hospital and surgeon volume
-
Barker F.G., Klibanski A., Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003, 88:4709-4719.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 4709-4719
-
-
Barker, F.G.1
Klibanski, A.2
Swearingen, B.3
-
44
-
-
0031607891
-
Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment
-
Dinc H., Esen F., Demirci A., et al. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 1998, 39:64-69.
-
(1998)
Acta Radiol
, vol.39
, pp. 64-69
-
-
Dinc, H.1
Esen, F.2
Demirci, A.3
-
45
-
-
0021988079
-
Pregnancy and the hyperprolactinemic woman
-
Molitch M.E. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985, 312:1364-1370.
-
(1985)
N Engl J Med
, vol.312
, pp. 1364-1370
-
-
Molitch, M.E.1
-
46
-
-
0020543027
-
Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas
-
Konopka P., Raymond J.P., Merceron R.E., et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983, 146:935-938.
-
(1983)
Am J Obstet Gynecol
, vol.146
, pp. 935-938
-
-
Konopka, P.1
Raymond, J.P.2
Merceron, R.E.3
-
47
-
-
0022639779
-
The safety of bromocriptine in long-term use: a review of the literature
-
Weil C. The safety of bromocriptine in long-term use: a review of the literature. Curr Med Res Opin 1986, 10:25-51.
-
(1986)
Curr Med Res Opin
, vol.10
, pp. 25-51
-
-
Weil, C.1
-
49
-
-
0022497825
-
Women with prolactinoma-effect of pregnancy and lactation on serum prolactin and on tumor growth
-
Holmgren U., Bergstrand G., Hagenfeldt K., et al. Women with prolactinoma-effect of pregnancy and lactation on serum prolactin and on tumor growth. Acta Endocrinol (Copenh) 1986, 111:452-459.
-
(1986)
Acta Endocrinol (Copenh)
, vol.111
, pp. 452-459
-
-
Holmgren, U.1
Bergstrand, G.2
Hagenfeldt, K.3
-
51
-
-
0024545674
-
The natural history of untreated hyperprolactinemia: a prospective analysis
-
Schlechte J., Dolan K., Sherman B., et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989, 68:412-418.
-
(1989)
J Clin Endocrinol Metab
, vol.68
, pp. 412-418
-
-
Schlechte, J.1
Dolan, K.2
Sherman, B.3
-
52
-
-
0026494897
-
The effect of combined estrogen/progesterone treatment in women with hyperprolactinemic amenorrhea
-
Fathy U.M., Foster P.A., Torode H.W., et al. The effect of combined estrogen/progesterone treatment in women with hyperprolactinemic amenorrhea. Gynecol Endocrinol 1992, 6:183-188.
-
(1992)
Gynecol Endocrinol
, vol.6
, pp. 183-188
-
-
Fathy, U.M.1
Foster, P.A.2
Torode, H.W.3
-
53
-
-
0027462619
-
The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia
-
Corenblum B., Donovan L. The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993, 59:671-673.
-
(1993)
Fertil Steril
, vol.59
, pp. 671-673
-
-
Corenblum, B.1
Donovan, L.2
-
54
-
-
75149154619
-
Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systemic review and meta-analysis
-
Dekkers O.M., Lagro J., Burman P., et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systemic review and meta-analysis. J Clin Endocrinol Metab 2010, 95:43-51.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 43-51
-
-
Dekkers, O.M.1
Lagro, J.2
Burman, P.3
|